首页 > 市场调查报告书 > 製药

生物製剂

质粒 DNA 合同製造全球市场研究报告 - 2023-2030 年行业分析、规模、份额、增长、趋势和预测

市场调查报告书

商品编码

1267347

质粒 DNA 合同製造全球市场研究报告 - 2023-2030 年行业分析、规模、份额、增长、趋势和预测

Global Plasmid DNA Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年04月01日 | 出版商:

Value Market Research | 英文 164 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球对质粒 DNA 合同製造市场的需求将从 2022 年的 3.1353 亿美元增长到 2030 年的近 15.8161 亿美元，预计 2023-2030 年研究期间的复合年增长率将达到 22.42%。

质粒 DNA 合同製造是将质粒 DNA 的製造外包给第三方合同製造商的过程。质粒 DNA 是一种用于各种应用的 DNA，例如基因治疗、疫苗开发和研究。与主染色体分离并可在细胞内独立復制的环状 DNA 片段。质粒 DNA 的合同製造通常涉及数十至数百克的大规模生产。

市场动态：

基因治疗需求的增长增加了对质粒 DNA 的需求，并推动了质粒 DNA 合同製造市场。此外，质粒 DNA 经常用于个性化医疗的开发，因为它可以根据特定患者的需求进行定制。这推动了对质粒 DNA 合同製造的需求。此外，质粒 DNA 製造技术的技术进步实现了高效且具有成本效益的製造，这促进了市场的增长。此外，不断增长的研究需求正在推动质粒 DNA 合同製造市场的增长。然而，监管要求可能会阻碍市场增长。

研究报告描述了波特的五力模型、市场吸引力分析和价值链分析。这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。此外，这些工具还可以对全球质粒 DNA 合同製造市场的每个细分市场进行全面评估。质粒 DNA 合同製造行业的增长和趋势为这项研究提供了一个整体方法。

市场细分：

本部分按国家/地区提供详细的细分数据，以帮助您确定每种产品/服务的目标受众和未来商机。

使用

细胞和基因疗法
免疫疗法
其他

按治疗领域

癌症
感染
自身免疫性疾病
心血管疾病
其他

由最终用户

製药和生物技术公司
关于研究机构

按地区分析：

本节介绍了区域前景，重点关注北美、欧洲、亚太地区、拉丁美洲、中东和非洲质粒 DNA 合同製造市场当前和未来的需求。此外，我们还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。质粒 DNA 合同製造市场的主要参与者包括 Charles River Laboratories、VGXI Inc.、PlasmidFactory GmbH &Co.KG、Boehringer Ingelheim、BioCina、TriLink Biotechnologies、Aster PTE.LTD、Thermo Fisher Scientific, Inc.、VIVE biotech、Lonza。本节概述了竞争格局，包括各种战略发展，例如主要併购、未来能力、合作伙伴关係、财务概览、合作、新产品开发和新产品发布。

内容

第一章前言

报告内容
- 目的
- 目标受众
- USP（独特的销售建议）及其提供的内容
调查范围
调查方法
- 市场调研流程
- 市场研究方法

第 2 章执行摘要

市场亮点
全球市场概况

第 3 章质粒 DNA 合同製造 - 行业分析

简介 - 市场动态
市场驱动力
市场製约因素
机会
行业趋势
波特的五力分析
市场吸引力分析
- 市场吸引力分析：按应用
- 按治疗领域进行市场吸引力分析
- 最终用户的市场吸引力分析
- 市场吸引力分析：按地区

第四章价值链分析

价值链分析
原材料分析
- 原材料清单
- 原材料製造商名单
- 主要原材料价格走势
潜在买家名单
营销渠道
- 直接营销
- 间接营销
- 市场发展趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章质粒 DNA 合同製造的全球市场分析：按应用

总结：按应用
过去和未来的数据
分析：按应用
细胞和基因疗法
免疫疗法
其他

第 7 章全球质粒 DNA 合同製造市场分析：按治疗领域分类

按治疗领域概述
过去和未来的数据
按治疗领域分析
癌症
感染
自身免疫性疾病
心血管疾病
其他

第 8 章最终用户的全球质粒 DNA 合同製造市场销售分析

最终用户总结
过去和未来的数据
最终用户分析
製药和生物技术公司
关于研究机构

第9章按地区分列的全球质粒DNA合同製造市场销售分析

按地区进行的销售前景分析
介绍销售分析
北美销售分析
- 概览、历史和预测销售分析
- 北美各部门的销售分析
- 北美销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史和预测销售分析
- 按细分市场进行的欧洲销售分析
- 按国家/地区划分的欧洲销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 意大利销售分析
- 俄罗斯销售分析
- 其他欧洲销售分析
亚太地区销售分析
- 概览、历史和预测销售分析
- 亚太地区各部门的销售分析
- 亚太国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本的销售分析
- 韩国销售分析
- 澳大利亚销售分析
- 其他亚太地区销售分析
拉丁美洲销售分析
- 概览、历史和预测销售分析
- 拉丁美洲各部门的销售分析
- 拉丁美洲国家/地区的销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利的销售分析
- 其他拉丁美洲销售分析
中东和非洲销售分析
- 概览、历史和预测销售分析
- 中东和非洲各细分市场的销售额分析
- 中东和非洲国家/地区的销售分析
- 沙特阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 其他中东和非洲销售分析

第10章质粒DNA代工企业的竞争状况

质粒 DNA 合同製造市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他扩展

第11章公司简介

前 10 名公司的市场份额分析
市场集中度
查尔斯河实验室
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
VGXI 公司
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
Plasmid Factory GmbH & Co. KG
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
勃林格殷格翰
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
生物中国
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
TriLink 生物技术公司
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
紫苑私人有限公司
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
Thermo Fisher Scientific Inc.
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
VIVE 生物技术公司
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势
龙沙
- 公司简介
- 企业收入
- 产品介绍
- 近期趋势

注意：在公司简介、财务细节、近期发展等方面，基于可用信息，私人控股公司可能不包括在内。

简介目录图表

Product Code: VMR112110153

The global demand for Plasmid DNA Contract Manufacturing Market is presumed to reach the market size of nearly USD 1581.61 MN by 2030 from USD 313.53 MN in 2022 with a CAGR of 22.42% under the study period 2023 - 2030.

Plasmid DNA contract manufacturing is the process of outsourcing the production of plasmid DNA to a third-party contract manufacturer. Plasmid DNA is a type of DNA used in various applications, including gene therapy, vaccine development, and research. It is a circular piece of DNA that is separate from the main chromosome and can replicate independently in a cell. Plasmid DNA contract manufacturing involves the production of plasmid DNA on a large scale, typically in the tens to hundreds of grams.

Market Dynamics:

The growing demand for gene therapy increases the need for plasmid DNA, which is driving the market for plasmid DNA contract manufacturing. Moreover, plasmid DNA is often used to develop personalized medicine, as it can be customized to specific patient needs. This is driving the demand for plasmid DNA contract manufacturing. Furthermore, technological advances in the production technology for plasmid DNA have made it more efficient and cost-effective, which has contributed to the market's growth. In addition, the rising demand for research drives the plasmid DNA contract manufacturing market growth. However, the regulatory requirements may impede the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of plasmid dna contract manufacturing. The growth and trends of plasmid dna contract manufacturing industry provide a holistic approach to this study.

Market Segmentation:

This section of the plasmid dna contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Cell & Gene Therapy
Immunotherapy
Others

By Therapeutic Area

Cancer
Infectious Diseases
Autoimmune Diseases
Cardiovascular Diseases
Others

By End-User

Pharmaceutical And Biotechnology Companies
Research Institutes

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Plasmid DNA Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the plasmid dna contract manufacturing market include Charles River Laboratories, VGXI Inc., PlasmidFactory GmbH & Co. KG, Boehringer Ingelheim, BioCina, TriLink Biotechnologies, Aster PTE. LTD, Thermo Fisher Scientific, Inc., VIVE biotech, Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PLASMID DNA CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Therapeutic Area
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Cell & Gene Therapy Historic and Forecast Sales by Regions
6.5 Immunotherapy Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET ANALYSIS BY THERAPEUTIC AREA

7.1 Overview by Therapeutic Area
7.2 Historical and Forecast Data
7.3 Analysis by Therapeutic Area
7.4 Cancer Historic and Forecast Sales by Regions
7.5 Infectious Diseases Historic and Forecast Sales by Regions
7.6 Autoimmune Diseases Historic and Forecast Sales by Regions
7.7 Cardiovascular Diseases Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY END-USER

8.1 Overview by End-user
8.2 Historical and Forecast Data
8.3 Analysis by End-user
8.4 Pharmaceutical And Biotechnology Companies Historic and Forecast Sales by Regions
8.5 Research Institutes Historic and Forecast Sales by Regions

9 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PLASMID DNA CONTRACT MANUFACTURING COMPANIES

10.1. Plasmid Dna Contract Manufacturing Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF PLASMID DNA CONTRACT MANUFACTURING INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Charles River Laboratories
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. VGXI Inc.
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. PlasmidFactory GmbH & Co. KG
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Boehringer Ingelheim
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. BioCina
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. TriLink Biotechnologies
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Aster PTE. LTD
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Thermo Fisher Scientific Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. VIVE biotech
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Lonza
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

简介目录图表